Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation  Kathryn F. Flack, Jay Desai, Jennifer M. Kolb, Prapti Chatterjee, Lars C. Wallentin, Michael Ezekowitz, Salim Yusuf, Stuart Connolly, Paul Reilly, Martina Brueckmann, John Ilgenfritz, James Aisenberg  Clinical Gastroenterology and Hepatology  Volume 15, Issue 5, Pages 682-690 (May 2017) DOI: 10.1016/j.cgh.2016.10.011 Copyright © 2017 AGA Institute Terms and Conditions

Figure 1 Flow chart of MGIB events in the RE-LY trial (N = 18,113) and those included in the current trial. The distribution of events of bleeding from GI cancers and those bleeding from noncancer or undiagnosed lesions is shown. Clinical Gastroenterology and Hepatology 2017 15, 682-690DOI: (10.1016/j.cgh.2016.10.011) Copyright © 2017 AGA Institute Terms and Conditions

Figure 2 Time from treatment initiation to MGIB in patients on (A) dabigatran and (B) warfarin. Comparisons between MGIB from cancer (solid line) vs MGIB from a noncancer or an unidentified source (dashed line). Clinical Gastroenterology and Hepatology 2017 15, 682-690DOI: (10.1016/j.cgh.2016.10.011) Copyright © 2017 AGA Institute Terms and Conditions